| Title |
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2012
|
| DOI | 10.1007/s00280-012-2028-2 |
| Pubmed ID | |
| Authors |
Sachi Morita, Keisuke Uehara, Goro Nakayama, Takashi Shibata, Tomoyo Oguri, Megumi Inada-Inoue, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Yuichi Ando |
| Abstract |
Bevacizumab, a monoclonal antibody that binds to VEGF, has a well-known toxic effect of hypertension. We studied possible associations between bevacizumab-related hypertension and gene polymorphisms to assure safer cancer therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Unknown | 21 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 27% |
| Researcher | 4 | 18% |
| Student > Master | 4 | 18% |
| Student > Doctoral Student | 2 | 9% |
| Student > Bachelor | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 2 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 59% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 14% |
| Agricultural and Biological Sciences | 2 | 9% |
| Environmental Science | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 2 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2021.
All research outputs
#7,155,520
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#620
of 2,501 outputs
Outputs of similar age
#73,341
of 280,759 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#7
of 27 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,759 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.